Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
Surfing the MASH Tsunami kicks off its 2023 wrap-up conversations with Jeff Lazarus, the 2023 winner of the Distinguished Scientific Achievement Award from the American Liver Foundation. Wrapping up 2023 in Steatotic Liver Disease: A Discussion with Jeff Lazarus
Profs. Laurent Castera and Scott Friedman join Louise Campbell and Roger Green to discuss highlights of the recent TLM2023 conference.
Dr. Zobair Younossi joins Roger Green to kick off our review coverage of TLM 2023. Dr. Younossi discusses the studies he presented at the meeting and discusses other work related to patient quality-of-life, economics of screening and treatment, and how stigma affects both patients and providers.
Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.
Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.
Roger Green is joined by Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final conversation explores a range of topics including the role of artificial intelligence and general observations around how the different questions being asked in 2023 versus 2019 demonstrate dramatic changes in how the field understands Fatty Liver disease.
Roger Green is joined by co-host Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This conversation also features comments around the subject of new NAFLD/NASH nomenclature.
Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final interview with Mazen is to be followed by a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions. Stay safe and surf on!
Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This is the first conversation of a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions.
